Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients
Authors' conclusion
Repeated vaccinations in many immunosuppressed patients produced antibody responses similar to those observed in HCs.
Study context
- Population
- Japanese patients with autoimmune rheumatic diseases (AIRD) receiving second and third BNT162b2 and/or mRNA-1273 vaccines; third dose six months after the second
- Participants
- 382 vs 326
- Exposure
- AIRD patients in 12 medication groups vs healthy controls
- AIRDn = 382
- Healthy controls (HCs)n = 326reference
- Outcome
- Humoral response (seroconversion and antibody titres, Elecsys Anti-SARS-CoV-2 S assay) to second and third mRNA vaccination
- Follow-up
- 3-6 weeks after the second and after the third vaccination
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
- Seroconversion rate and antibody titres lower in AIRD patients than in HCs after the second and the third vaccination
- Seroconversion rates <90% after the third vaccination with mycophenolate mofetil and rituximab
- Antibody levels after the third vaccination significantly lower than HCs with TNF inhibitor with or without methotrexate, abatacept and rituximab or cyclophosphamide (multivariate, adjusted for age, sex, GC dosage)
- Adequate humoral response after the third vaccination with sulfasalazine, bucillamine, MTX monotherapy, iguratimod, IL-6 inhibitors or calcineurin inhibitors including tacrolimus
Observational data: associations, not effects.
Original publication
Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients. Rheumatology (Oxford). Published 8 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →